Molecular Neurobiology and Promising New Treatment in Depression
The limited effects of currently available antidepressants are becoming an urgent issue in depression research. It takes a long time to determine treatment effects, and the overall remission rate is low. Although we expect the development of non-monoamine antidepressants in the near future, efforts...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/17/3/381 |
id |
doaj-1fe4fcb3be5444539bf84beae24a6488 |
---|---|
record_format |
Article |
spelling |
doaj-1fe4fcb3be5444539bf84beae24a64882020-11-24T22:18:45ZengMDPI AGInternational Journal of Molecular Sciences1422-00672016-03-0117338110.3390/ijms17030381ijms17030381Molecular Neurobiology and Promising New Treatment in DepressionSang Won Jeon0Yong-Ku Kim1Department of Psychiatry, College of Medicine, Korea University, Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Seoul 15355, KoreaDepartment of Psychiatry, College of Medicine, Korea University, Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Seoul 15355, KoreaThe limited effects of currently available antidepressants are becoming an urgent issue in depression research. It takes a long time to determine treatment effects, and the overall remission rate is low. Although we expect the development of non-monoamine antidepressants in the near future, efforts in this regard over the past several decades have not yet been compensated. Thus, researchers and clinicians should clarify the neurobiological mechanisms of integrated modulators that regulate changes in genes, cells, the brain, and behaviors associated with depression. In this study, we review molecular neurobiological theories and new treatments for depression. Beyond neuroanatomy and monoamine theory, we discuss cells and molecules, neural plasticity, neurotrophisms, endocrine mechanisms, immunological mechanisms, genetics, circadian rhythms, and metabolic regulation in depression. In addition, we introduce the possibility of new antidepressant drug development using protein translation signaling (mTOR) pathways.http://www.mdpi.com/1422-0067/17/3/381depressionneurobiologyantidepressantneural plasticityBDNFendocrineimmunegenemTOR |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sang Won Jeon Yong-Ku Kim |
spellingShingle |
Sang Won Jeon Yong-Ku Kim Molecular Neurobiology and Promising New Treatment in Depression International Journal of Molecular Sciences depression neurobiology antidepressant neural plasticity BDNF endocrine immune gene mTOR |
author_facet |
Sang Won Jeon Yong-Ku Kim |
author_sort |
Sang Won Jeon |
title |
Molecular Neurobiology and Promising New Treatment in Depression |
title_short |
Molecular Neurobiology and Promising New Treatment in Depression |
title_full |
Molecular Neurobiology and Promising New Treatment in Depression |
title_fullStr |
Molecular Neurobiology and Promising New Treatment in Depression |
title_full_unstemmed |
Molecular Neurobiology and Promising New Treatment in Depression |
title_sort |
molecular neurobiology and promising new treatment in depression |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2016-03-01 |
description |
The limited effects of currently available antidepressants are becoming an urgent issue in depression research. It takes a long time to determine treatment effects, and the overall remission rate is low. Although we expect the development of non-monoamine antidepressants in the near future, efforts in this regard over the past several decades have not yet been compensated. Thus, researchers and clinicians should clarify the neurobiological mechanisms of integrated modulators that regulate changes in genes, cells, the brain, and behaviors associated with depression. In this study, we review molecular neurobiological theories and new treatments for depression. Beyond neuroanatomy and monoamine theory, we discuss cells and molecules, neural plasticity, neurotrophisms, endocrine mechanisms, immunological mechanisms, genetics, circadian rhythms, and metabolic regulation in depression. In addition, we introduce the possibility of new antidepressant drug development using protein translation signaling (mTOR) pathways. |
topic |
depression neurobiology antidepressant neural plasticity BDNF endocrine immune gene mTOR |
url |
http://www.mdpi.com/1422-0067/17/3/381 |
work_keys_str_mv |
AT sangwonjeon molecularneurobiologyandpromisingnewtreatmentindepression AT yongkukim molecularneurobiologyandpromisingnewtreatmentindepression |
_version_ |
1725781843734691840 |